Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-029/ Neulasta (Neulastim) when given subcutaneously in patients with Chemotherapy Induced Neutropenia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Reliance Life Sciences
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 New trial record